Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term dalteparin safety and efficacy in chronic neuroischaemic diabetic foot ulcers (extension study)
2008-001566-90Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dalteparin in diabetic foot ulcer (DFU), peripheral artery occlusion (PAD) and type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoint: Total number of hemorrhages. Started May 2008; status: terminated.
02
Drugs
dalteparin
03
Conditions
diabetic foot ulcer (DFU)peripheral artery occlusion (PAD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-001566-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001566-90.